Subsequently, we evaluated the inhibitory ability of the peptide by titrating the concentration of alanine-substituted p53 TAD PEP by combining FITC-labeled p53 TAD PEP and FOXO4 FHD (Figure
A detailed symptom diary documenting the timing, duration, triggers, and associated physical sensations can clarify whether symptoms correlate with medication administration, meals, or gastrointestinal side effects
Moreover, since the drugs rate of dissociation from its protein-binding partner is determined by the proteins affinity for the drug of choice, it may, one day, be possible to modify the specific site of the protein so that the drug would be released at a predetermined rate, maintaining the proper concentration of free drug in the bloodstream
Evaluation of melanotanII, a superpotent cyclic melanotropic peptide in a pilot phaseI clinical study